section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: changes in BP, peripheral edema, QT interval prolongation, tachycardia.

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), MELANOMA, photosensitivity, rash, SQUAMOUS CELL CARCINOMA, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS.

EENT: visual disturbances, eye hemorrhage.

Endo: ADRENAL INSUFFICIENCY.

F and E: hyperglycemia, hypokalemia, hypomagnesemia.

GI: abdominal pain, diarrhea, HEPATOTOXICITY, nausea, pancreatitis, vomiting.

MS: fluorosis, periostitis.

Neuro: dizziness, hallucinations, headache.
Misc: chills, fever, infusion reactions.

Interactions

Drug-Drug:

Drug-Natural Products:

Availability

(Generic available)

Route/Dosage

see Calculator

Invasive Aspergillosis, Scedosporiosis, or Fusariosis

Hepatic Impairment

Candidemia in Non-Neutropenic Patients or Other Deep Tissue Candida Infections

Hepatic Impairment

Esophageal Candidiasis

Hepatic Impairment

US Brand Names

Vfend

Action

Therapeutic Effects:

Spectrum:

Classifications

Therapeutic Classification: antifungals

Pharmacologic Classification: azoles

Pharmacokinetics

Absorption: 96% absorbed following oral administration; IV administration results in complete bioavailability.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Primarily metabolized by liver via the CYP2C19, CYP2C9, and CYP3A4 isoenzymes; <2% excreted unchanged in urine. The CYP2C19 isoenzyme exhibits genetic polymorphism; 15–20% of Asian patients and 3–5% of Caucasian and Black patients may be poor metabolizers and may have significantly voriconazole concentrations and an risk of adverse effects.

Half-life: Dose-dependent (adults: 6–9 hr); in hepatic impairment.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid1–2 hr12 hr
IVrapidend of infusion12 hr

Patient/Family Teaching

Pronunciation

vor-i-KON-a-zole